2026 Speakers
Luiza Abdo, PhD, Brazilian National Cancer Institute
Prasad Adusumilli, Deputy Chief, Thoracic Surgery, Vice Chair, Department Of Surgery, Memorial Sloan-Kettering Cancer Center
Jamie Almeida, Biologist, N.I.S.T. - National Institute of Standards and Technology.
Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine
Jared Auclair, Director of Bioinnovation, Northeastern University
Daniel Baker, PhD, University of Pennsylvania
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Cecile Bauche, CSO, Alaya.bio
Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Kristin Grant Beaumont, Associate Professor, Icahn School of Medicine, Mount Sinai
Vladimir Bermudez, Associate Director, Columbia Institute for Cell Engineering and Therapy, Columbia University Irving Medical Center
Rachel Beyer, Director, Vector Production Facility, National Cancer Institute
Sulagna Bhattacharya, CEO, Nanoscope Therapeutics
Debaditya Bhattacharya, Vice President, CMC Technical Development, MyrtelleGTX
Alexander Blood, Associate Director, Accelerator for Clinical Transformation, Mass General Brigham
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Rajeev Boregowda, Associate Director, Sanofi
Anne Brooks, SVP, Global Access, Operations and Proleukin, Iovance Biotherapeutics
Catherine Brownstein, Assistant Professor, Harvard Medical School
Kimberly Burlison, Market Access, North America, Orchard Therapeutics
Frederic Bushman, Professor and Chair, Department of Microbiology, Co-Director PennCHOP Microbiome Program, Perelman School of Medicine University of Pennsylvania
Ying Cai, Executive Director, Manufacturing Science and Technology, Ultragenyx Pharmaceutical Inc.
Marcus Calkins, Director of Scientific Communication, Genomefrontier Therapeutics Inc
Brian Campbell, VP & GM, US, Orchard Therapeutics
Yu (Clay) Cao, Vice President, Global Head of Drug Discovery, GenEditBio Limited
James Carroll, President and CEO, RNA Nanobiotics
Daniel Chafamo, M.D. Candidate, Perelman School of Medicine University of Pennsylvania
Preet Chaudhary, CEO, Angeles Therapeutics
Fred Chereau, SVP, Strategy and Business Development, Alexion Pharmaceuticals
Therese Choquette, Head of Analytical and Translational Sciences, Tigen Pharma
Michelle Christian, Sr Director of Quality and Technical Operations, KSQ Therapeutics, Inc.
Daniel Cohen, Senior Director, Vector Engineering Genomics and Computational Biology, Roche Innovation Center
Caralynn Collens, CEO, Dimension Bio
Angela Columbano, Head Business Development and Partnership, Genethon
Mike Conway, Vice President, Talent and Learning | People & Culture, Bluerock Therapeutics
Gregory Cost, Vice President, Distinguished Scientific Fellow, Addition Therapeutics
Terry Cothran, Chief Pharmacy Officer, Oklahoma Health Care Authority
TJ Cradick, CSO / Principal, Gene Editing Frontiers LLC
Colleen Dansereau, Vice President, Emerging Discoveries, Gene Therapy Operations, Boston Children's Hospital
Houman Dehghani, Vice President, Technical Development, Cabaletta Bio
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Francesco Destro, Head of Engineering, BioCurie
Wenjun Di, Senior Scientist, Ultragenyx Pharmaceutical Inc.
Robert Dillman, Chief Medical Officer, AIVITA Biomedical, Inc.
Scott Donohue, Senior Director, Market Access, Deerfield Management
Tracy Dowling, Chief Business Officer & General Counsel, AskBio
Pierre Dromel, CTO & Founder, InGel Therapeutics
Mark Duckworth, Sr. Director Cellular and Gene Therapy Operations, Children's Hospital of Philadelphia
Mark Dudley, Consultant, Independent Advisors
George Eastwood, Executive Director, Emily Whitehead Foundation
Matt Edwards, Vice President, Process Science, Affinia Therapeutics
Kate Excoffon, Founder and CEO, Gene Tx Optimized, LLC
Steven Feldman, Site Head and Scientific Director, Stanford GMP Facility, Stanford School of Medicine/Stanford HealthCare
Madelyn Fell, Director of Operations, Cell Therapy and Transplant, University of Pennsylvania Health System
Allen Feng, Chief Scientific Officer, HebeCell Corporation
Miguel Forte, CEO, Kiji Therapeutics and President, International Society of Cell and Gene Therapy, Kiji Therapeutics
Patrick Gailliot, Sr. Director, Patient Operations, Abeona Therapeutics
Hugh Gannon, Associate Director, KSQ Therapeutics, Inc.
Zhenghong Gao, Chief Strategy Officer, Zhongmou Therapeutics
Maurits Geerlings, President & CEO, NanoCell Therapeutics
Xuecui Guo, SVP, Gene Regulation, Meiragtx
Erin Harris, Chief Editor, Cell & Gene
Els Henckaerts, Professor, KU Leuven
Friederike Herbst-Nowrouzi, Director of the Human Genome Editing Laboratory (HGEL), Perelman School of Medicine University of Pennsylvania
Katie Hodges, President and Owner, KAH Management, LLC
Spencer Hoover, Principal, SH Consulting LLC
Amy House, VP Corporate Development and Communications, Beacon Therapeutics
Brett Howard, Senior Director, US Regulatory Policy, United States Pharmacopeia
Dennis Huang, Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development, Ultragenyx
Xiao Huang, Assistant Professor, Precision Immune Engineering Laboratory, Drexel University
Ruud Hulspas, Director Process Development, Dana-Farber Cancer Institute
Selene Ingusci, Research Instructor, University of Pittsburgh
Scott Jeffers, Chief Technology Officer, GenSight Biologics
Jennifer Johnston, Cofounder and CEO, NysnoBio
Micheala Jones, Lead, Global Medical Affairs, Hemophilia Gene Editing (CRISPR/Cas9) and Thrombosis, Regeneron
Margareth Jorvid, Board Member, Elicera Therapeutics
Angela Justice, Executive Coach & Advisor, Justice Group Advisors
Stephan Kadauke, Associate Professor of Clinical Pathology and Lab Medicine, The Children's Hospital of Philadelphia
Manoj Kandpal, Director of Research Bioinformatics at the Center for Clinical and Translational Science, Rockefeller University
Kumar Karyampudi, Senior Director, Cell Therapies, Moffitt Cancer Center
William Kearns, Co-founder & CSO, Lugenica
Manolis Kellis, Professor, Computer Science, MIT
Chirag Khatiwala, Head of CMC and Technical Operations, Rarity PBC
Koby Kidder, Principal Scientist & Co-Inventor, BobcatBio
Daniel KIlbank, CSO, Mygogenesis LLC
Sven Kili, Partner, Saisei Ventures
Eric Kmiec, Founder & CEO, CorriXR Therapeutics
Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute
Richard Koya, Professor, University of Chicago School of Medicine, University of Chicago
Stephan Krause, Executive Director, Analytical Strategy, Bristol Myers Squibb
Chien-Tsun Kuan, President / CEO and Co-Founder, ARCE Therapeutics Inc.
Edward Kwee, Biologist, National Institute of Standards and Technology
Tom Leitch, CTO, KSQ Therapeutics, Inc.
Roy Levitt, Clinical Professor, Director, UHealth Institute for Advanced Pain Management Center, UNIVERSITY OF MIAMI
Yan Li, Senior Director, Process Development, Cabaletta Bio
Kok-Seong Lim, Independent Expert, Independent Expert
Hernando Lopez-Bertoni, Associate Professor, Johns Hopkins Medicine
George Magrath, CEO, Opus Genetics
Shivani Maikhuri, Sr. Project Manager, Children's Hospital of Philadelphia
Ram Mandalam, CEO, Stealth Biotech
Oscar Marcos Contreras, Assistant Professor, Temple University
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
Craig T. Martin, Professor of Chemistry, University of Massachusetts Amherst
Chris Mason, Professor, Cell & Gene Therapy, University College London
Mukesh Mayani, Senior Director, Global CMC Development, Ultragenyx
Joshua McGee, CSO & Co-founder, Keylicon Biosciences
Michael McMahon, Professor, Johns Hopkins School of Medicine and Kennedy Krieger Institute, John Hopkins School Of Medicine
Monica Michail, Oncology/Hematology Research Pharmacist, Hackensack Meridian Health
Fiona Miller, Managing Partner, quadraScope Ventures
Avanish Mishra, Assistant Professor of Bioengineering, Harvard Medical School and Mass General Hospital, Harvard Medical School
Dara Missan, Lead Engineer, QC, Mayo Clinic
Dora Mitchell, Senior Vice President of Operations, Chief of Staff, Interius BioTherapeutics, Inc.
Samarendra Mohanty, President and Chief Scientific Officer, Nanoscope Therapeutics
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Christopher Murriel, Vice President, Pre-Clinical Pharmacology, ArsenalBio
Prachi Narayan, End-to-End Clinical & Development Lead and Strategic Advisor– ATMPs, Independent Expert
Vanessa Almendro Navarro, Chief Commercialization Officer, City of Hope
Cokey Nguyen, CSO, Atara Biotherapeutics
Parul Nisha, Senior Director, Clinical and Medical Affairs, Cook MyoSite Inc
Natascha Nolet, Sr. Manager, Abeona Therapeutics
Lynn O'Donnell, Director, Cell Therapy Manufacturing & Engineering, The Ohio State University
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Andrea Penn, Commercial Learning & Development Director, Autolus
David Peritt, Chief Scientific Officer, Lupagen
Wenning Qin, Senior VP, Innovation & Process Development, eGenesis Inc
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Kim Raineri, Chief Technology Officer, Aspen Neuroscience
Niraj Ramachandran, Senior Regulatory Program Director - Cellular Therapies Pharma Technical Cell and Gene Therapy (PTC), Genentech
Brock Reeve, CEO, Eos BioInnovation
Michael Riotto, Grassroots Advocacy Leader, International Myeloma Foundation
Natalia Rivera-Torres, Associate Director of Pre-Clinical Development & Research Operations, Gene Editing Institute
Blaine Robinson, Vice President, Therapy Acceleration Program, Blood Cancer United
Irene Rombel, President and CEO, BioCurie
Roelof Rongen, CEO, Adolore Biotherapeutics
Johanna Rossell, Senior Vice President, General Manager, Rare Disease, Sumitomo Pharma America Inc
Qian Ruan, SVP of Technical Operations, Arcturus Therapeutics
Holger Russ, Scientific Co-Founder, Tolerance Bio
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Arthur Sagoskin, Chief Scientific Development Officer, Mygogenesis
Tay Salimullah, Venture Partner, 4BIO Capital
Amber Salzman, Chief Executive Officer, Epicrispr Biotechnologies
Jorge Santiago Ortiz, VP, CMC and Regulatory, Apertura Gene Therapy
Sumona (Fed) Sarkar, Biomedical Engineer, NIST USA
Mary Schaheen, President, Prevail Partners LLC
Vishal Shah, Dean, Division of the Math, Science and Health Careers, Community College of Philadelphia
Daniel Shelly, Chief Business Development Officer, Immuthera
Alex Sherman, Director, Center for Innovation and BIoinformatics, Mass General Brigham
Lara Silverman, Principal Consultant, L.I.S. BioConsulting
Justin Skoble, Vice President of Technical Operations, Caribou Biosciences
Devyn Smith, CEO, Arbor Biotechnologies
Andrew Steinsapir, Director of Gene Therapy Program Lead, Deerfield Management
Swami Subramanian, Head of Global Pricing and Contracting Strategy, Regeneron
Shankar Swaminathan, Team Lead Drug Product Readiness CMC, Astellas
Yvette Tanhehco, Associate Professor of Pathology and Cell Biology, Medical Director of Cellular Therapy Laboratory, Columbia University
Kelli Tea, Head of Commercial, Cartesian Therapeutics
Sally Tucker, Chief Medical Officer, Opus Genetics
Nelly Viseux, VP, Cell Therapies Development, Manufacturing, Supply & Quality, Regeneron
Jim Wang, VP, Global Regulatory Strategy, Genetic Medicines, Regeneron
Xiao Wang, Assistant Professor, University of Pennsylvania
Jie Wei, Director, Bioanalytical Sciences, Tr1x, Inc
Daniel Weiss, Professor, University of Vermont
Michael White, Founder, ViroSpark
Morgan Wolfe, Associate Director, Patient Operations, Abeona Therapeutics
Karrie Wong, VP of Cell Therapy, KSQ Therapeutics, Inc.
Howard Wu, Co-Founder & Chief Scientific Officer, Full Circles Therapeutics
Yuntao Wu, Professor, George Mason University
Sareina Wu, Founder & CSO, Genomefrontier Therapeutics Inc
Lingyue yan, Scientist III, AbbVie
Poh Yeh-Chuin, VP, Head of Tech Ops, Tolerance Bio
Satoshi Yoshiji, Assistant Professor, McGill University/Broad Institute, McGill University
Holly Young, Facility Director, ACTL, Sanford Stem Cell Institute, UC San Diego
Haiqing Yu, Principal Scientist, Team Manager & Tech Lead, Sanofi
David Zuzga, Associate Dean of Biomedical Studies, The Wistar Institute
Get Involved with the Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events